darapladib
Small moleculeexperimental
Darapladib is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis. — Wikipedia
Clinical trial activity
21 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT01916720)
Timeline
Indications
Mechanism of action
- LDL-associated phospholipase A2INHIBITOR
PLA2G7 inhibitor
Reversible oral inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2- Mol. weight
- 666.79 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDarapladib ↗
- ChEMBLCHEMBL204021 ↗
Also known as
- darapladib
- darapladib
- darapladib
- sb480848
- sb 480848
- sb 480848
- sb-480848
- sb-480848
- sb-480848
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02058641 | Phase 1 | Feb 26, 2014 | GlaxoSmithKline |
| NCT02000804 | Phase 1 | Oct 23, 2013 | GlaxoSmithKline |
| NCT01873339 | Phase 1 | Jun 19, 2013 | GlaxoSmithKline |
| NCT01852565 | Phase 1 | May 14, 2013 | GlaxoSmithKline |
| NCT01751074 | Phase 1 | Dec 1, 2012 | GlaxoSmithKline |
| NCT01711723 | Phase 1 | Oct 1, 2012 | GlaxoSmithKline |
| NCT01506895 | Phase 2 | Feb 1, 2012 | GlaxoSmithKline |
| NCT01154114 | Phase 1 | Jul 1, 2010 | GlaxoSmithKline |
| NCT01067339 | Phase 3 | Feb 4, 2010 | GlaxoSmithKline, Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA) |
| NCT01000727 | Phase 3 | Dec 1, 2009 | GlaxoSmithKline, The TIMI Study Group |
| NCT00799903 | Phase 3 | Dec 1, 2008 | GlaxoSmithKline |
| NCT00743860 | Phase 1 | Sep 1, 2008 | GlaxoSmithKline |
| NCT00734032 | Phase 2 | Aug 1, 2008 | GlaxoSmithKline |
| NCT00704431 | Phase 1 | May 1, 2008 | GlaxoSmithKline |
| NCT00622830 | Phase 1 | Jan 1, 2008 | GlaxoSmithKline |
| NCT00551317 | Phase 1 | Jul 1, 2007 | GlaxoSmithKline |
| NCT00411073 | Phase 1 | Dec 1, 2006 | GlaxoSmithKline |
| NCT00368576 | Phase 1 | Aug 1, 2006 | GlaxoSmithKline |
| NCT00268996 | Phase 2 | Nov 10, 2005 | GlaxoSmithKline |
| NCT00269048 | Phase 2 | Nov 1, 2005 | GlaxoSmithKline |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 21 | 20 | 3 | 2003 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2010 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2010 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2010 |
| The TIMI Study Group | Academic/Hospital | 1 | 0 | 1 | 2009 |
5 organizations
Page 1 / 1